**Supplementary Table S2.** Summary of efficacy at week 48 in PPS

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Efficacy indicators | TMF group (n = 89) | | Blank control group (n = 86) | | P | |
| Serum HBV-DNA<20 IU/mL |  | |  | | <0.001 | |
| Number of patients, n (%) [95%CI] | 66 (74.2) [63.8-82.9] | | 5 (5.8) [1.9-13.0] | |  | |
| Proportion difference between TMF and blank control, % [95%CI] | 68.3 [58.0-78.7] | | - | |  | |
| Serum HBV-DNA level |  | |  | | <0.001 | |
| <20 IU/mL | 66 (74.2) | | 5 (5.8) | |  | |
| 20-2000 IU/mL | 19 (21.3) | | 33 (38.4) | |  | |
| >2000 IU/mL | 4 (4.5) | | 48 (55.8) | |  | |
| Serum HBV-DNA |  | |  | |  | |
| Log10 IU/mL, median (Q1, Q3) | 1.00 (1.00, 1.41) | | 3.43 (2.66, 5.21) | | <0.001 | |
| Change from baseline (log10 IU/mL), median (Q1, Q3) | -2.68 (-4.90, -1.94) | | -0.15 (-0.66, 0.04) | | <0.001 | |
| Percentage change from baseline (%), median (Q1, Q3) | -72.69 (-77.36, -65.54) | | -3.97 (-19.00, 0.61) | | <0.001 | |
| HBeAg-positive subjects achieving HBeAg loss, n (%) | 0 | | 1 (4.5) | | 0.489 | |
| HBeAg-positive subjects achieving HBsAg loss and HBeAg seroconversion, n (%) | 0 | | 1 (4.5) | | 0.489 | |
| HBsAg loss, n (%) | 1 (1.1) | | 0 | | >0.999 | |
| HBsAg loss and HBSAg seroconversion, n (%) | 1 (1.2) | | 0 | | >0.999 | |
| HBsAg |  | |  | |  | |
| Log10 IU/mL, median (Q1, Q3) | 3.32 (2.47, 4.13) | | 3.23 (2.37, 4.00) | | 0.702 | |
| Change from baseline (log10 IU/mL), median (Q1, Q3) [n=188] | -0.07 (-0.16, -0.01) | | -0.04 (-0.09, 0.02) | | 0.011 | |
| Percentage change from baseline (%), median (Q1, Q3) [n=188] | -2.63 (-4.23, -0.57) | | -1.33 (-2.74, 0.76) | | 0.012 | |
| Liver stiffness measurement |  | |  | |  | |
| kPa, median (Q1, Q3) [n=185] | 5.30 (4.80, 6.60) | | 5.40 (4.50, 6.15) | | 0.386 | |
| Change from baseline (kPa), median (Q1, Q3) [n=184] | -0.05 (-0.73, 1.00) | | 0.20 (-0.90, 1.15) | | 0.931 | |
| Percentage change from baseline (%), median (Q1, Q3) [n=184] | -0.79 (-11.54, 22.88) | | 3.92 (-16.40, 21.96) | | 0.984 | |
| FIB4 |  | |  | |  | |
| Median (Q1, Q3) | 0.99 (0.72, 1.37) | | 0.92 (0.64, 1.13) | | 0.22 | |
| Change from baseline, median (Q1, Q3) [n=191] | 0.00 (-0.11, 0.11) | | 0.00 (-0.11, 0.10) | | 0.81 | |
| Percentage change from baseline (%), Median (Q1, Q3) [n=191] | -0.22 (-11.16, 10.48) | | 0.36 (-10.17, 15.55) | | 0.747 | |
| ALT |  | |  | |  | |
| Median (Q1, Q3) | 20.00 (16.00, 27.90) | | 20.00 (17.00, 25.08) | | 0.572 | |
| Change from baseline, median (Q1, Q3) [n=192] | -3.00 (-8.00, 1.25) | | 0.00 (-5.75, 3.00) | | 0.012 | |
| Percentage change from baseline (%), median (Q1, Q3) [n=192] | -14.09 (-33.33, 7.48) | | 0.00 (-22.65, 16.67) | | 0.012 | |
| ALT flare | | 0 | | 0 | | - | |

\*ALT flare: During the study, subjects experienced ALT >2 ULN (40 IU/L for HBeAg-positive patients or ALT > ULN (40 IU/L) for HBeAg-negative patients), and other causes were excluded by the investigators.

PPS: per-protocol set; TMF: tenofovir amibufenamide; CI: confidence interval; HBV-DNA: hepatitis B virus DNA; Q: quartile; HBsAg: hepatitis B surface antigen; HBeAg: hepatitis B e-antigen.